MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
11.49
+0.61 (5.61%)
Apr 29, 2026, 12:00 PM EDT - Market open
MiNK Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -12.49 | -10.78 | -22.46 | -27.99 | -30.21 | |
| Depreciation & Amortization | 0.18 | 0.22 | 0.2 | 0.12 | 0.08 | |
| Loss (Gain) From Sale of Assets | 0.17 | -0.19 | - | - | - | |
| Stock-Based Compensation | 2.67 | 1.81 | 3.86 | 3.03 | 1.74 | |
| Other Operating Activities | 0.25 | -1.07 | -0.27 | -2.79 | 11.83 | |
| Change in Accounts Payable | 0.69 | -1.18 | -1.92 | 2.66 | -0.15 | |
| Change in Other Net Operating Assets | 2.6 | 1.64 | 4.81 | 6.11 | 3.89 | |
| Operating Cash Flow | -5.93 | -9.56 | -15.76 | -18.87 | -12.83 | |
| Capital Expenditures | - | - | -0.07 | -0.25 | -0.25 | |
| Investing Cash Flow | - | - | -0.07 | -0.25 | -0.25 | |
| Long-Term Debt Issued | - | 5 | - | - | 9.46 | |
| Net Debt Issued (Repaid) | - | 5 | - | - | 9.46 | |
| Issuance of Common Stock | 14.9 | 5.82 | 0.07 | 0 | 46 | |
| Repurchase of Common Stock | -0.17 | - | -0.48 | -0.16 | - | |
| Other Financing Activities | - | - | - | - | -6.2 | |
| Financing Cash Flow | 14.72 | 10.82 | -0.41 | -0.16 | 49.26 | |
| Foreign Exchange Rate Adjustments | -0.01 | -0.05 | -0.03 | 0.02 | 0.02 | |
| Net Cash Flow | 8.78 | 1.21 | -16.27 | -19.25 | 36.2 | |
| Free Cash Flow | -5.93 | -9.56 | -15.84 | -19.12 | -13.08 | |
| Free Cash Flow Per Share | -1.39 | -2.53 | -4.61 | -5.68 | -5.02 | |
| Cash Interest Paid | 0.01 | 0.01 | 0.03 | 0.01 | - | |
| Levered Free Cash Flow | -4.23 | -8.62 | -11.08 | -20.25 | -8.67 | |
| Unlevered Free Cash Flow | -4.23 | -8.62 | -11.08 | -20.25 | -7.15 | |
| Change in Working Capital | 3.29 | 0.46 | 2.9 | 8.77 | 3.74 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.